Cell Biology Program
The Michael Overholtzer Lab
Research
The Overholtzer lab studies mechanisms of nutrient sensing and cellular responses to nutrient starvation, including the nutrient recycling pathway autophagy, scavenging pathways such as macropinocytosis, and mechanisms of cell death. We investigate cell death mechanisms that have unique effects on cell populations, including entosis that supports the survival of starved cells and promotes cell competition, and ferroptosis that eliminates starved cell populations by propagating from cell to cell. The lab also studies mechanisms that regulate autophagy protein and lysosome function in endocytic trafficking and nutrient homeostasis.
Research Projects
Featured News
Publications Highlights
People
Michael Overholtzer, PhD
Dean, Gerstner Sloan Kettering Graduate School
- Cell biologist Michael Overholtzer studies the mechanisms of tumor initiation and progression, cell adhesion, and cell death.
- PhD, Princeton University
- [email protected]
- Email Address
- 212-639-6536
- Office Phone
Members
- National University of Singapore
- Virginia Polytechnic Institute and State University
- BS, University College Utrecht
- MB, University of Pennsylvania
Lab Alumni
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Postdoctoral Fellow
Get in Touch
-
Lab Head Email
-
Office Phone
-
Lab Phone
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Michael Overholtzer discloses the following relationships and financial interests:
-
Elucida Oncology
Intellectual Property Rights
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].